~,, High-dose intravenous nicardipine has been shown to reduce the incidence of angiographic and symptomatic vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH), but treatment may be complicated by side effects, including hypotension or pulmonary edema/azotemia. From August, 1989, to January, 1991 patients at 2l neurosurgical centers were entered into a randomized double-blind trial comparing high-dose (0.15 mg/kg/hr) nicardipine with a 50% lower dose (0.075 mg/kg/hr) administered by continuous intravenous infusion for up to 14 days following SAH. Patients in all neurological grades were eligible for the study.
c
ALCIUM antagonist drugs, such as the dihydropyridine antagonists nimodipine and nicardipine, have been increasingly employed as adjuncts in the management of patients with aneurysmal subarachnoid hemorrhage (SAH). 1 Recently it was shown in a large multicenter randomized double-blind placebo-controlled trial that treatment with large doses of intravenous nicardipine administered as a continuous infusion for 14 days following SAH was associated with a reduction in symptomatic, as well as angiographic, vasospasm. 6,7 However, adverse side effects, including hypotension, pulmonary edema, and renal dysfunction, led to premature discontinuation of nicardipine in 14% of patients. Premature discontinuation of nicardipine treatment was not infrequently followed by the onset of ischemic neurological deficits in this unprotected population.
Since the dose of nicardipine administered in the placebo-controlled trial was nearly 10 times higher in biological equivalents than the currently recommended dose ofnicardipine for SAH patients (Syntex Research, unpublished data), the present study was undertaken to examine whether a 50% lower dose of nicardipine might be equally (or perhaps more) effective in preventing ischemic deficits from vasospasm and, at the same time, safer in terms of a reduced number and severity of side effects. The results of this randomized double-blind trial of high-dose versus 50% dose of nicardipine in patients with recent aneu~'smal SAH are the subject of this report.
Clinical Material and Methods

Patient Selection
Patients for this study were selected from all patients with SAH admitted to 23 hospitals in 21 centers in the United States and Canada.* The study protocol and informed consent form were approved for use by each institution's Institutional Review Board. Criteria for entry were identical Io those in the placebo-controlled trial published previouslyr Briefly, a patient was eligible for the study if: 1) the patient was aged 18 years or older; 2) SAH was confirmed by computerized tomography (CT) or lumbar puncture (all neurological grades were eligible); 3) angiography demonstrated a saccular aneurysm; and 4) the patient could begin therapy at a participating hospital between Days 0 and 7 (Day 0 being the calendar day of the hemorrhage) following the most recent hemorrhage.
A patient was excluded from the trial if: 1) the aneurysm was fusiform, traumatic, or mycotic; 2) severe complicating medical illnesses were present; 3) the patient was receiving a calcium antagonist drug at the time of the hemorrhage; 4) the patient had suffered another neurological or psychiatric illness that might confound the neurological evaluation; 5) the patient had a history of allergy to or intolerance of calcium antagonist drugs; 6) the patient was known or suspected to be pregnant; or 7) legal informed consent could not be obtained.
Randomization
After initial screening was performed and informed consent obtained, eligible patients were randomly assigned in equal ratio to receive either standard highdose (0.15 mg/kg/hr) or low-dose (0.075 mg/kg/hr) nicardipine by continuous intravenous infusion for up to 14 days following SAH, at which time the infusion was to be discontinued. The nicardipine preparations were diluted to equal volumes to preserve study blinding. Blocked random assignment to the two treatment groups was accomplished within each center. The randomization sequence was generated by Syntex Research and was kept blinded from the staff of the Central Registry of the Cooperative Aneurysm Study as well as the participating investigators until the study had been completed and the data audited and finalized.
Study Drug Regimen
If clinically feasible, all patients received 500 cc of colloid solution just prior to the beginning of study drug infusion in order to ameliorate any hypotensive side effects attending nicardipine administration. Following colloid infusion, the study drug infusion was begun at one-half the planned infusion rate and maintained for 8 hours. If no signs of intolerance developed, the infusion rate was increased to 75% of the planned rate for another 8 hours, and then finally to the full dose. If intolerance developed, as evidenced by hypotension or other adverse effects, the dosage rate was titrated back by 50% and then either increased again or discontinued if adverse effects persisted. Blood urea nitrogen was monitored at least every other day; if it exceeded 30 mg/dl, the dose was halved or discontinued.
* Participating centers and personnel are listed in the Appendix.
Thus, all patients were to receive the full planned dose or the maximally tolerated fraction of the planned dose.
Use of any other calcium antagonist during the treatment period was prohibited. Conventional therapy for symptomatic vasospasm, such as intentional hypervolemia (prophylactically or therapeutically), induced hypertension, and/or mannitol administration, was allowed at the discretion of the treating investigator. Experimental therapies for vasospasm, such as angioplasty or intrathecal thrombolytic therapy, were prohibited. Decisions regarding the timing of aneurysm surgery and the use of antifibrinolytic drugs, steroids, or other adjunctive therapies were left to the participating investigators.
Endpoints
Endpoinls examined for the study were complication rates, rates of premature discontinuation of study drug, incidence of ischemic deficits due to vasospasm (symptomatic vasospasm), incidence of death and disability due to vasospasm, incidence and volume of infarction on a CT scan obtained at 3 months, overall outcome at 3 months as assessed according to the Glasgow Outcome Scale (GOS) s by a blinded evaluator, and the results of a graded neurological examination (National Institutes of Health (NIH) Stroke Scale ~ and Folstein Mini-Mental StateS). Symptomatic vascspasm was diagnosed using clinical criteria. 6 
Patient Monitoring
The incidence of neurological worsening during the treatment period was also monitored. Neurological worsening was defined as a decline of two or more points in the daily modified (all four limbs scored for motor score) Glasgow Coma Scale score 9 or an increase of two or more points in the motor score on the NIH Stroke Scale. When neurological worsening was recognized, the investigators were required to designate a primary cause and all contributing causes, as well as the treatment initiated for the neurological worsening.
Angiographic Studies
Copies of cerebral angiograms obtained for clinical indications between Days 7 and 11 following SAH were sent to the Central Registry for blinded measurement of the incidence and severity of angiographic vasospasm. Angiographic vasospasm, if present, was graded as mild, moderate, or severe] Additionally, if transcranial Doppler ultrasound studies were available, mean blood flow velocity in each middle cerebral artery (MCA) was measured and recorded at baseline, between Days 7 and 11, on Day 14, at the time of neurological worsening, and at additional times if clinically indicated. the Kruskal-Wallis test. The Kaplan-Meier method was used to generate mortality curves, and comparisons were made with the log rank test. All tests used a significance level of 0.05.
Data Analysis
Results
From September, 1989, to January, 1991, 365 patients were entered into the trial. The trial was terminated before the planned 600 patients were accrued because of problems discovered with the shelf life of the nicardipine supplies. The lowest detected potency in the study drug supply was 86% of the labeled concentration. The majority (73%) of the patients in the trial received full potency (> 90%) of the drug.
During the entry period, 397 patients with SAId admitted to the participating centers were excluded from the study. Reasons for exclusion were: lack of angiographic demonstration of an aneurysm (27%); use of another calcium antagonist at the time of SAH (17%); presence of other severe complicating illnesses (15%); study accrual temporarily suspended (12%); inability to begin therapy within 7 days of SAH (6%); presence of a nonsaccular aneurysm (4%); and inability to obtain informed consent (4%). Other exclusion criteria were present for 10% of these patients, with each comprising less than 3%. Patients may have had more than one exclusion criterion. Of the 365 study subjects, 184 were randomly assigned to receive standard dose nicardipine (high-dose group) and 181 were assigned to receive 50% of the standard dose (low-dose group). Table 1 shows the admission characteristics and prognostic factors for vasospasm and outcome in the patients in each group. There were proportionally more women in the lowdose group (74% vs. 61%, p < 0.01), and the mean height and weight of the patients in this group were less than in the high-dose group. There were no statistically significant differences in mean patient age, admission neurological condition, admission systolic or diastolic blood pressure, or the amount and distribution of blood clot present on the admission CT scan. FrG. 1. Graph illustrating the cumulative onset of ischemic deficits due to vasospasm in patients treated with either highdose or low-dose nicardipine. There are no statistically significant differences at any of the time points, given in days. There were also no significant differences in the number, size, or distribution of aneurysms demonstrated on the admission angiograms. The incidence of preexisting medical conditions was similar in both groups ( Table 2 ), except that there was a trend toward more patients in the high-dose group having a prior history of malignancy. Concomitant management practices were similar between the two groups, except for a trend toward more frequent use of antifibrinolytic drugs in the low-dose group (11.1% vs. 5 .6%, p = 0.06) and a trend toward more patients in the low-dose group undergoing aneurysm surgery after the 1st week ( Table 3 ). The frequency of use of prophylactic or therapeutic hypervolemic/hypertensive therapy was not significantly different between the groups. Other rescue therapies, such as angioplasty, were used infrequently in both groups (five patients (2.8%) in the low-dose group vs. two patients (1.1%) in the high-dose group).
Patients in the low-dose group received on average (-+ standard deviation) 10.2 _+ 3.9 days of study drug compared to 9.5 +_ 4.1 days in the high-dose group (p = 0.07). Patients in the high-dose group received a significantly smaller proportion of the total planned dose than patients in the low-dose group (80% _+ 0.2% vs. 86% + 0.2%, p = 0.02). Treatment was terminated prematurely in 18% of patients in the high-dose group because of an adverse medical event, compared to 10% in the low-dose group (p = 0.03). There was a preponderance of discontinuation of high-dose therapy due to .pulmonary edema, arrhythmia, and relative hypotenslon or inability to induce hypertension (Table 4) .
Neurological Change
Ischemic symptoms attributed to vasospasm were reported in 31.5% of low-dose and 31.0% of high-dose nicardipine-treated patients. The timing of the onset of symptoms was not significantly different between the groups (Fig. 1) . Twelve patients in the high-dose group (7%) suffered the onset of symptomatic vasospasm following premature discontinuation of the study drug due to an adverse event, compared to six patients in the low-dose group (3%) (difference not significant). Neurological worsening occurred in 65 (36%) of low-dose and 62 (34%) of high-dose nicardipine-treated patients. The frequency of neurological worsening by primary or contributing cause after randomization was not significantly different between the groups (Table 5 ), except that 5% more patients in the low-dose group had worsening due to unknown causes (p = 0.05).
Arterial Narrowing
A total of 199 patients underwent transcranial Doppler ultrasound examinations between Days 7 and 11 (Table 6 ). Patients in the low-dose group were more likely to be female, and there was a trend toward more frequent use of antifibrinolytic drugs in the low-dose group. More patients in the low-dose group had mean MCA flow velocities above 120 cm/sec in each of three velocity groupings (Fig. 2) , but the differences were not statistically significant. Follow-up cerebral angiography was performed in 17% of patients in the low-dose group between Days 7 and 11 following SAH, compared to 24% of patients in the high-dose group (p = 0.11). A greater (although not statistically significant) proportion of patients without symptoms of vasospasm had follow-up angiograplay in the high-dose group (17% vs. 12%), while the proportion of patients with symptomatic vasospasm who underwent angiography was more similar in the two groups (7% in the high-dose group vs. 5% in the low-dose group). Among patients with angiography FIc. 2. Bar graph demonstrating the distributions of maximum mean middle cerebral artery (MCA) flow velocities, as measured by transcranial Doppler ultrasonography between Days 7 and 11 following subarachnoid hemorrhage in patients treated with either high-dose or low-dose nicardipine. A greater proportion of patients treated with low-dose nicardipine had MCA flow velocities above 120 cm/sec, but the differences were not statistically significant. performed between Days 7 and 11, the baseline characteristics and prognostic factors for vasospasm were not significantly different between the groups, except that a greater proportion of low-dose nicardipinetreated patients were female (Table 7 ). In the low-dose group, 39% had moderate or severe angiographic vasospasm versus 19% in the high-dose group (p = 0.08) (Fig. 3) .
Clinical Outcome
At follow-up evaluation, which ranged from 3 to 411 days (median 100 days in the low-dose group, 96 days in the high-dose group), overall outcome as assessed using the GOS was similar in both groups (Fig. 4) . A good recovery was achieved in 59% of patients in the low-dose group and 12% died, while 58% of patients in the high-dose group made a good recovery and 11% died. The causes of death and disability are shown in Table 8 . While there were no statistically significant differences in the primary causes of death and disability, vasospasm was cited more frequently as a primary or contributing cause of death or disability in the lowdose group than in the high-dose group (12.5% vs. 5.7%, p = 0.03).
The NIH Stroke Scale and Mini-Mental State scores were not significantly different in survivors at follow-up examination (Table 9 ). Seventy-two (56%) of 128 low-dose and 73 (59%) of 124 high-dose nicardipine-treated patients had cerebral infarctions detected on follow-up CT scans. The volumes of the measured infarctions were not significantly different between the groups, and the prognostic factors for vasospasm were balanced between the groups in the subset of patients who underwent follow-up CT. Among those patients who had infarcts detected, the median infarct 3 . Bar graph showing the severity of vasospasm in patients with follow-up cerebral angiograms obtained between Days 7 and I 1 following subarachnoid hemorrhage. A greater proportion of patients in the high-dose group had no detectable angiographic vasospasm, and the differences in the overall distributions were statistically significant (p < 0.05, Fisher's exact test). volume was 9.1 cc in the low-dose group and 12.3 cc in the high-dose group (not significant).
Complications
The incidence of over 50 medical and neurological complications was monitored during the study. The incidence of hypotension, defined as a systolic blood pressure of less than 100 mm Hg, was not significantly different between the groups, occurring in 28% of patients in the low-dose group and 33% of patients in the high-dose group. Severe hypotension, that is, lifethreatening with symptoms of end organ ischemia, occurred in 0.6% of low-dose and 1.1% of high-dose nicardipine-trealed patients. Mean systolic and diastolic blood pressures were not significantly different between the groups on any day during treatment. Relative hypotension, defined as a systolic blood pressure that fell below baseline, but not to less than 100 mm Hg, was reported with similar frequency in both groups (8% in the low-dose group vs. 10% in thc high-dose group, p = not significant), and the inability to induce therapeutic hypertension (failed hypertension) was also reported similarly in both groups (6% in the low-dose group vs. 5% in the high-dose group, p = not significant). The incidence of renal dysfunction was 13% in the low-dose group and 16% in the high-dose group (p = not significant). Phlebitis at the injection site was reported in 14% of patients in the high-dose group compared to 8% of low-dose nicardipine-treated patients (p = 0.11).
FIo. 4. Bar graph illustrating the overall outcomes as deterrnined using the Glasgow Outcome Scale s in all patients randomly assigned to treatment with either low-dose or highdose nicardipine. There were no statistically significant differences in any of the outcome strata.
Pulmonary edema was reported in 34% of high-dose compared to 20% of low-dose nicardipine-treated patients, a statistically significant difference (p < 0.01). Pulmonary edema was judged to be severe or fifethreatening in 0.5% of patients in the high-dose group versus 1.7% of patients in the low-dose group. The only other complication reported at significantly different rates was the syndrome of inappropriate anlidiuretic hormone secretion, which was reported more frequently in the low-dose group (6% vs. 1%, p < 0.05).
Discussion
The results of this randomized dosing study of the dihydropyridine calcium antagonist nieardipine sug- gest that 0.075 mg/kg/hr by continuous intravenous infusion is better tolerated in patients with recent aneurysmal SAH than the high dose of 0.15 mg/kg/hr. Adjustment of the results by sex did not alter any of the conclusions. The incidence of symptomatic vasospasm and the overall clinical outcome were virtually identical with either dose regimen. As with any small study showing no significant differences, a type 2 statistical error cannot be excluded, but the sample size is robust enough to generate power in excess of 80% for detecting an absolute 15% increase in symptomatic vasospasm in the low-dose group, if it really existed. Therefore, it seems unlikely that any clinically important differences in outcome exist between the two dosing schemes. Similar power exists for detection of differences in complication rates. The mechanism underlying the association between high-close nicardipine and pulmonary edema remains uncertain, Perhaps this represents a form of "highoutput" pulmonary edema produced by the profound lowering of systemic vascular resistance attending nicardipine administration in some patients.~l,J2 In any event, the evidence is strong that intravenous nicardipine may be associated with this complication, and prompt recognition and appropriate dosage modifications may be lifesaving in some cases. The results of this study are remarkably consistent with the results of the placebo-controlled trial of intravenous nicardipine in SAH reported previously. ~,7 The incidence of symptomatic vasospasm observed with either dose of nicardipine tested in this study (31% to 32%) is similar to the rate reported in the nicardipine group in the previous trial (31.6%), which was clearly lower than the rate reported in the placebo-treated group (45.5%). Of note is the finding that the mortality rate in both groups in the present study (11.5%) was better than that in the high-dose nicardipine group in the placebo-controlled trial (17%) (p < 0.01). As the patients appeared to be similar at baseline, the reasons for the apparent improvement in the mortality rate in the present study are not clear.
One question not completely settled by the observation in this trial is whether there is a difference in the incidence or severity of arterial narrowing between the two dosage groups. Flamm and colleagues, 4 in their open dose-escalation trial, observed a significant reduction in angiographic vasospasm with administration of nicardipine at a dose of 0.15 mg/kg/hr compared to lower doses. However, patients in that trial were not randomly assigned to dosage groups. In the current study, selection bias, as evidenced by the difference in proportions between the groups of patients with angiograms performed on Days 7 to 11 and the tendency for more asymptomatic patients in the high-dose group to be studied, may have at least partially accounted for the observation of more angiographic vasospasm in the low-dose group. The sample sizes are larger for the ultrasound study data, and the apparent differences in the incidence and severity of vasospasm are smaller and not statistically significant.
Even if there is a dose-dependent difference in angiographic vasospasm, it is not apparent clinically. There was no difference in either the incidence or severity (as determined by daily neurological examinations) of ischemic deficits from vasospasm observed during hospitalization, and the incidence and volume of measured CT infarction were nearly the same at follow-up evaluation. Vasospasm was cited more frequently as a contributing cause of disability at follow-up review in the low-dose group, but attribution of the cause of disability in this critically ill population of patients is notoriously difficult. 1~
Conclusions
These observations suggest that nicardipine at a dose of 0.075 mg/kg/hr via continuous intravenous infusion is better tolerated and may be as effective as administration at a dose of 0.15 mg/kg/hr in patients with aneurysmal SAH. From a practical standpoint, the ability to titrate the dose of nicardipine to individual tolerance (watching for hypotension, renal dysfunction, and pulmonary edema) makes it a potentially very useful drug in the management of these critically ill patients.
APPENDIX
Participants in the Study
Clinical centers participating in this study:
Barrow Neurological Institute, Phoenix, and University of Arizona, Tucson, Arizona. 
